Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

65.97 +0.40 (+0.61%)
Streaming Delayed Price Updated: 10:09 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response ↗
Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin... 
Via Benzinga
News headline image
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study ↗
The company is hoping to treat a rare disease that causes patients to experience severe reactions to sunlight. 
Via Investor's Business Daily
News headline image
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
NASDAQ:IRON Shareholder Notice: Investigation over Potential Wrongdoing at Disc Medicine Opco Inc ↗
San Diego, CA -- (SBWIRE) -- 12/08/2023 -- Certain directors of Disc Medicine Opco Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
Where Disc Medicine Stands With Analysts ↗
 
Via Benzinga
News headline image
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
News headline image
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
Pamela Stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches 
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
From Disc Medicine Inc
Via GlobeNewswire
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
News headline image
BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.